Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO

Start Date15 Dec 2025

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT07392281

/ RecruitingEarly Phase 1IIT

Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina

Angina with non-obstructive coronary arteries (ANOCA) is highly prevalent, impairing quality of life and independently associated with cardiovascular events, yet effective treatments are lacking. The endothelin-1 (ET-1)-endothelin receptor (ETR) system is pivotal in ANOCA pathogenesis. Preclinical studies show that ETR blockade or pericyte-specific knockout of ETA receptor improves coronary microcirculatory function in models of myocardial ischemia-reperfusion and diabetes. Clinical evidence indicates ETR antagonists can enhance microvascular endothelial function and myocardial perfusion in ANOCA patients. However, prior studies diagnosed ANOCA based only on symptoms and angiography without precise microvascular functional assessment. Early ETR antagonists also showed frequent adverse effects (e.g., edema, headache), reducing treatment satisfaction. To address this, the investigators will conduct an open-label, single-center, single-arm trial using invasive coronary microcirculatory function testing to accurately phenotype ANOCA and assess microvascular changes. Patients on standard therapy will receive macitentan-a novel ETR antagonist with improved vasodilatory efficacy and safety-to evaluate its effects on coronary microcirculatory function, angina symptoms, and adverse events. Additionally, the investigators will perform multi-omics profiling (proteomics, transcriptomics, metabolomics) on patient blood samples to identify molecular signatures linked to ANOCA subtypes and treatment response, providing evidence for precision intervention strategies in ANOCA.

Start Date01 Sep 2025

Sponsor / Collaborator

China-Japan Friendship Hospital

TCTR20231103004

/ Not yet recruitingPhase 1

Bioequivalence Study of 10 mg Macitentan Film-coated Tablets in Healthy Thai Male Volunteers

Start Date30 May 2025

Sponsor / Collaborator

Unison Laboratories Co. Ltd.

100 Clinical Results associated with Macitentan

100 Translational Medicine associated with Macitentan

100 Patents (Medical) associated with Macitentan

545

Literatures (Medical) associated with Macitentan

01 Apr 2026·PEDIATRIC CARDIOLOGY

Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience

Article

Author: A. Sabaté-Rotés ; L. Albert de la Torre ; A. Moya Bonora ; J. M. Espín López ; A. Rodriguez Ogando ; M. J. del Cerro Marin ; C. Labrandero de Lera

Macitentan seems to improve outcomes in patients with pulmonary arterial hypertension (PAH). Nevertheless, safety and efficacy in pediatric patients is still to be determined. Multi-center, observational study to assess safety and efficacy of oral macitentan in patients under 18 years-of-age from the Spanish Registry of Pediatric Pulmonary Hypertension with group 1 PAH. Outcome measures included changes in the World Health Organization Functional Class (WHO FC) from baseline to month 6, 6-min walking distance (6MWD), NT-proBNP levels, risk-stratification, echocardiographic and hemodynamic parameters, and Pediatric Quality of Life Inventory. Seventy-four patients (median age 9.6 years) with PAH were included in the study, of which thirty-one had idiopathic/heritable pulmonary arterial hypertension and 43 had PAH associated with congenital heart disease. Significant clinical improvement was observed after 6 months of treatment with macitentan: The percentage of patients on WHO FC III/IV decreased from 48 to 22% (p = 0.001); mean 6MWD (n = 42) increased significantly in around 45 m (p = 0.032); NT-proBNP decreased a mean of - 438.9 ± 175 pg/ml, (p = 0.015). There was a 17% increase in the number of patients meeting all three low-risk parameters of 17% (p = 0.002). Side effects were detected in four patients (5.4%). Macitentan was discontinued in one patient. Disease progression was observed in 6 patients despite macitentan therapy. This study provided evidence on the clinical benefits and good tolerance of macitentan in paediatric population with group I PAH treated in routine clinical practice.

01 Mar 2026·JOURNAL OF HEART AND LUNG TRANSPLANTATION

Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension

Article

Author: Jing, Zhi-Cheng ; Heresi, Gustavo A ; Ghofrani, Hossein-Ardeschir ; Jaumdally, Noormaa ; Madani, Michael M ; Lack, Gabriela ; Kim, Nick H ; Csonka, Dénes ; Jenkins, David P ; Guth, Stefan ; Mayer, Eckhard ; Cerovic, Sofija ; Matsubara, Hiromi ; McGuire, Erin ; Humbert, Marc

BACKGROUND:

In a phase 2 study of inoperable chronic thromboembolic pulmonary hypertension (CTEPH), macitentan 10 mg improved hemodynamics and exercise capacity.

METHODS:

MACiTEPH (NCT04271475) was a prospective, double-blind, placebo-controlled, phase 3 study. Adult patients with inoperable CTEPH (with/without balloon pulmonary angioplasty [BPA]) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA) (with/without BPA) were randomized 1:1 to macitentan 75 mg or placebo once daily. Primary endpoint was change from baseline to Week 28 in 6-minute walk distance (6MWD).

RESULTS:

Following a pre-planned interim analysis, the study was stopped for futility. 127 patients were randomized, predominantly with inoperable CTEPH with BPA (36.2%) or persistent/recurrent CTEPH after PEA without BPA (30.7%). The majority (81.9%) were receiving pulmonary hypertension (PH)-specific therapy at baseline. 47 patients in the macitentan 75 mg and 48 in the placebo group had Week 28 assessments. Primary endpoint was not met; mean change in 6MWD from baseline to Week 28 versus placebo was -16.1 m (95% confidence limit: -32.3, 0.16). Clinical worsening events occurred in 6.3% and 14.3% of patients in the macitentan 75 mg and placebo groups, respectively. A slightly higher proportion of the macitentan 75 mg group had ≥1 adverse event (AE) or serious AE versus placebo; no pattern was identified. More patients in macitentan 75 mg versus placebo group discontinued treatment due to an AE (21.9% versus 7.9%, respectively).

CONCLUSIONS:

MACiTEPH was discontinued for futility, as no treatment effect on 6MWD (primary endpoint) was observed. Despite the higher discontinuation rate in the macitentan 75 mg group, no unexpected safety signals were observed in CTEPH patients.

01 Mar 2026·JOURNAL OF PEDIATRICS

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial

Article

Author: Ivy, D Dunbar ; Borissoff, Julian I ; Cerovic, Sofija ; Beghetti, Maurice ; Csonka, Dénes ; Remeňová, Tatiana ; Berger, Rolf M F ; Villeneuve, Matthieu ; Richard, Dominik

OBJECTIVES:

To evaluate pharmacokinetics (PK), efficacy, and safety of macitentan vs standard of care (SoC) in pediatric pulmonary arterial hypertension (PAH).

STUDY DESIGN:

TOMORROW was a multi-center, open-label, phase 3 clinical trial in patients aged ≥2-<18 years with WHO-FC I-III. Patients were randomized (1:1) to macitentan (bodyweight-based dosing) or SoC (≤2 PAH-specific therapies). The primary endpoint was steady-state C_trough plasma concentration of macitentan and aprocitentan (active metabolite) at week 12. Secondary endpoints included: time-to-first clinical event committee (CEC)-confirmed disease progression, safety/tolerability, change in NT-proBNP, and quality of life (QoL).

RESULTS:

We randomized 148 patients (macitentan: n=73; SoC: n=75). The PK profile was consistent with adults; mean (SD) steady-state C_trough concentrations were 185 (114.3) and 983 (324.1) ng/mL. Mean treatment duration was 183.36 weeks (macitentan) and 130.59 weeks (SoC). Hazard ratios (95% CI) for time-to-event analyses (macitentan vs SoC) were 0.828 (0.460-1.492) for disease progression, 0.912 (0.393-2.118) for PAH hospitalization and 1.530 (0.429-5.457) for PAH mortality (P>0.05 for all). Percentage of baseline NT-proBNP was 72% (macitentan) vs 101% (SoC) at week 12 (P=0.086) and 76% vs 78% at week 24 (P=0.884). Macitentan showed clinically meaningful improvements in QoL assessments vs SoC for children (P=0.043) and parents (P=0.020) at week 24. The safety profile of macitentan was consistent with that seen in adults.

CONCLUSIONS:

TOMORROW was a novel study assessing PK and the long-term efficacy and safety of macitentan vs SoC in pediatric PAH. The results confirm the adequacy of the macitentan dosing in this population and provided signals of potential benefit of macitentan over SoC for children with PAH.

News (Medical) associated with Macitentan

27 Apr 2026

·www.biospace.com

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

BOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm for serious, rare respiratory diseases, today announced two appointments that further strengthen its leadership team as the company advances its clinical programs and prepares for future commercialization. Adam Golden, a seasoned legal and business adviser with over three decades of experience advising biopharma companies, was appointed General Counsel and Head of Business Development. Frank Salisbury, an established leader in launching multiple FDA-approved therapies, including ESBRIET ® (pirfenidone) for idiopathic pulmonary fibrosis (IPF), was appointed Senior Vice President, Commercial. “We are thrilled to welcome Adam and Frank to Avalyn at this important stage in our evolution,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “Adam brings deep legal experience guiding life sciences companies through critical inflection points involving business development and legal strategy, all of which will be invaluable as we transition to life as a public company. Frank has a proven track record of building and leading commercial organizations for innovative respiratory treatments, including oral pirfenidone for IPF and sotatercept for PAH. Their expertise strengthens our ability to execute across corporate strategy, business operations, and commercial readiness as we advance our pipeline and position Avalyn for long-term success.” Adam Golden has over 30 years of experience advising biopharma companies, spanning legal, business development, and corporate strategy. Prior to joining Avalyn, Mr. Golden was a Partner and Global Head of Life Sciences at Freshfields LLP, where he founded and led the build-out of an internationally recognized life sciences practice. Previously, he served as Partner and Head of the New York Corporate Practice Group at Hogan Lovells, and spent over two decades at Kaye Scholer, where he held multiple roles, including Partner and Co-Chair, Corporate Department. Over the course of his career, Mr. Golden has advised on mergers and acquisitions, strategic collaborations, corporate governance, and SEC compliance. He currently serves on the Board of Advisors for Life Science Cares. Mr. Golden holds a J.D. from New York University School of Law and an A.B. in Chemistry from Princeton University. Frank Salisbury brings more than 24 years of commercial leadership experience across biotechnology and large pharmaceutical companies, with a focus on rare respiratory diseases. Over the course of his career, he has played a key role in the launch and commercialization of multiple therapies. At InterMune/Genentech, he led the U.S. launch and served as National Head of Sales for ESBRIET ® (pirfenidone) in IPF. He also held senior commercial roles at Acceleron Pharma, where he supported the launch of WINREVAIR ® for pulmonary arterial hypertension (PAH), as well as at Actelion, where he played a core role in the commercialization of OPSUMIT ® (macitentan) for PAH. He joins Avalyn from PureTech Health, where he was the Senior Vice President for Commercial and Product Strategy. Mr. Salisbury earned a B.A. in International Relations and an M.B.A. from Stanford University, and was a Fulbright Scholar in Germany, where he studied HIV prevention interventions. About Avalyn Pharma Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging tolerability and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone data. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn. Investor Contact: Cassie Saitow, Avalyn Pharma Inc. Sr. Director, IR and Corporate Communications ir@avalynpharma.com Media Contact: Kat Lippincott, Deerfield Group kat.lippincott@deerfieldgroup.com media@avalynpharma.com

Phase 2Executive Change

08 Jan 2026

·www.biopharmadive.com

Diagonal banks another $125M for ‘clustering’ antibody drugs

Biotechnology startup Diagonal Therapeutics has added $125 million to its coffers, the company said Thursday, in a Series B round that will propel its first drug prospect into the clinic this year.Many antibody drugs are designed to block signaling pathways implicated in the progression of diseases, such as tumor growth in cancer or inflammation in immunological disorders. Diagonal is working on specialized kinds of multi-pronged clustering antibodies that bind to cellular receptors and force them together in a specific shape. These contortions result in different signals that may be able to switch on a pathway thats been disrupted by disease.The companys first attempt at the concept is DIAG723. With it, the company is homing in on two conditions: a rare genetic disease called hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, a disorder that affects the lungs and heart. The company had originally sought to develop separate drugs for each disease, but found that a singular clustering antibody might impact both of them by reactivating a signaling complex called ALK1, said Alex Lugovskoy, the biotechs CEO.Given that we are addressing the foundational defect in these diseases, that gives us a lot of confidence that it would be a mechanism that could be beneficial in patients, Lugovskoy said.Hereditary hemorrhagic telangiectasia affects an estimated 150,000 people in the U.S. and Europe. The disease triggers the development of abnormal blood vessels that can rupture and lead to bleeds as well as chronic anemia. Treatments only help with symptoms, leaving room for a therapy that, like DIAG723, might be able to address the conditions root cause.Theres more competition in pulmonary arterial hypertension, for which Merck & Co.s Winrevairrecently approved and other options like Johnson & Johnsons Opsumit and Uptravi and United Therapeutics Tyvaso can alleviate symptoms. But Lugovskoy sees DIAG723 as a potentially complementary therapy to treatments like Winrevair.Behind DIAG723 in its pipeline are unnamed prospective treatments for iron overload and chronic kidney disease.Sanofi Ventures and Janus Henderson Investors co-led Diagonals Series B round, which involved more than a dozen investors in total. Those two firms, he said, were particularly attractive because of Sanofis vibrant hematology franchise, and Janus Hendersons level of understanding of a medicine development path when we go forward.Other participating firms included Deep Track Capital, Atlas Venture, RA Capital Management, Frazier Life Sciences and Viking Global Investors. The company has now raised more than $250 million since emerging from stealth in 2024. '

07 Jul 2025

·www.einpresswire.com

Endothelin Receptor Antagonist REMS Information

Based on a new analysis of human pregnancy data compiled from the use of endothelin receptor antagonist (ERA) medicines for two decades, FDA has determined that risk evaluation and mitigation strategy (REMS) requirements related to embryofetal toxicity (EFT) risk are no longer necessary to ensure the benefits of ERA medicines outweigh those risks. The Agency’s current assessment is that labeling alone is adequate to communicate the risk, and labeling will continue to inform health care professionals and patients of the risk. In April 2025, FDA eliminated the REMS for the following ERA medicines: Eliminated REMS ERA Medicine Ambrisentan Shared System REMS Letairis and generics (ambrisentan) Macitentan-Containing Products Shared System REMS Opsumit and generics (macitentan) Opsynvi (macitentan and tadalafil) Tryvio REMS Tryvio (aprocitentan) Elimination of these REMS means: Health care professionals can prescribe and dispense ambrisentan, macitentan-containing products, and Tryvio (aprocitentan) without enrolling or participating in a REMS. Patients can receive ambrisentan and macitentan-containing products without enrolling in a REMS; the Tryvio REMS did not require patient enrollment. Pharmacies and health care facilities can dispense ambrisentan, macitentan-containing products, and Tryvio (aprocitentan) without enrolling or participating in a REMS. Additionally, FDA notified manufacturers of the following ERA medicines that they must modify the REMS to remove requirements related to EFT risk. FDA will notify prescribers, pharmacies, and patients when these REMS have been modified in fall 2025. REMS requirements related to hepatotoxicity (liver damage) risk for these ERA medicines will remain in effect. Modified REMS ERA Medicine Bosentan Shared System REMS Tracleer and generics (bosentan) Filspari REMS Filspari (sparsentan) ERA prescribing information and EFT risk Information about EFT and mitigation of this risk will remain in the prescribing information for ERA medicines. Use of ERA medicines is contraindicated in pregnancy. Based on data from animal EFT studies, pregnant patients should not use ERA medicines as they may cause fetal harm. Patients who can get pregnant should ensure they are not pregnant prior to starting treatment with an ERA medicine and use effective contraception while taking an ERA medicine. Prescribers should exclude pregnancy prior to treatment initiation and advise patients who can get pregnant of the potential risk to a fetus and of the need to use effective contraception while they are treated with an ERA medicine. Basis for removing ERA REMS requirements for EFT risk FDA regularly assesses the benefits and risks of REMS programs and may eliminate a REMS or remove certain components of a REMS if, after review of REMS assessments or other information, we determine that the extra measures in a REMS are no longer necessary to ensure a medication’s benefits outweigh its risks. FDA’s ERA REMS requirements for EFT risk were based on findings from animal studies. Over time, the Agency monitored clinical outcomes reported in patients exposed to ERA medicines during pregnancy and observed that these data did not show a pattern of congenital malformations consistent with what was observed in animal EFT studies. Given the Agency's new analysis and understanding of clinical risk, FDA determined that labeling for all ERA medicines is sufficient to provide information about EFT risk and its mitigation. Whom do I contact? Prescribers, pharmacies, and patients may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov with questions. Adverse events, medication errors, or quality problems experienced with ERA medicines should be reported to FDA's MedWatch Adverse Event Reporting program . FDA’s top priority is patient safety, and we will continue to monitor the safety of these drugs. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Macitentan

External Link

KEGG	Wiki	ATC	Drug Bank
D10135	Macitentan	C02KX04	DB08932

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Familial Primary Pulmonary Hypertension	Australia	Janssen-Cilag Pty Ltd.	05 Feb 2014
Idiopathic pulmonary arterial hypertension	Australia	Janssen-Cilag Pty Ltd.	05 Feb 2014
Pulmonary arterial hypertension associated with congenital heart disease	Australia	Janssen-Cilag Pty Ltd.	05 Feb 2014
Pulmonary arterial hypertension associated with connective tissue disease	Australia	Janssen-Cilag Pty Ltd.	05 Feb 2014
Pulmonary Arterial Hypertension	United States	Actelion Pharmaceuticals US, Inc.	18 Oct 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension, Pulmonary	Phase 3	Hungary	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Hypertension, Pulmonary	Phase 3	Poland	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Hypertension, Pulmonary	Phase 3	Russia	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Hypertension, Pulmonary	Phase 3	South Korea	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Hypertension, Pulmonary	Phase 3	Thailand	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Hypertension, Pulmonary	Phase 3	Vietnam	Actelion Pharmaceuticals Ltd.	20 Nov 2024
Chronic thromboembolic pulmonary hypertension	Phase 3	Belarus	Actelion Pharmaceuticals US, Inc.	05 Apr 2018
Chronic thromboembolic pulmonary hypertension	Phase 3	Belgium	Actelion Pharmaceuticals US, Inc.	05 Apr 2018
Chronic thromboembolic pulmonary hypertension	Phase 3	France	Actelion Pharmaceuticals US, Inc.	05 Apr 2018
Chronic thromboembolic pulmonary hypertension	Phase 3	Poland	Actelion Pharmaceuticals US, Inc.	05 Apr 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02932410 (TOMORROW, Pubmed \| J Pediatr)	Phase 3	Pulmonary Arterial Hypertension	148	Macitentan	shscmtnini(ndzbuqdivw) = lcxwmijebl fmjjyqulte (loyixlzcjn ) View more	Positive	01 Mar 2026
				Standard of Care (≤2 PAH-specific therapies)	shscmtnini(ndzbuqdivw) = zuhigxrvpc fmjjyqulte (loyixlzcjn ) View more
NCT05167825 (PAH3001, Company_Website) Manual	Phase 3	Pulmonary Arterial Hypertension	-	Macitentan	omvynjrwmq(nrnpxfoqjk) = wqhurimerh ftqxselnua (nctuafiewz ) Met	Positive	22 Dec 2025
NCT02932410 (TOMORROW, Company_Website) Manual	Phase 3	Pulmonary Arterial Hypertension	148	Opsumit	osbwnsnswa(xfczbcfmwd) = jcuhddkgjv hfwpkxhild (tregbxhhcs ) View more	Positive	22 Dec 2025
				Standard of Care (SoC)	axenaleqqn(riwkiiycic) = xmrpmaryrb ioqftvsdmz (luuaqecjbc )
NCT05167825 (PAH3001, CTgov)	Phase 3	Pulmonary Arterial Hypertension	7	Macitentan	yqcicvjbic(lykifqnfsu) = xzgwygruai bdahlwvghm (appdbtbjwn, 75.1) View more	-	21 Oct 2025
NCT02932410 (TOMORROW, CTgov)	Phase 3	Familial Primary Pulmonary Hypertension \| Pulmonary Arterial Hypertension	165	Macitentan (Macitentan (JNJ-67896062) (>=2 Years))	gabrfkacvi(ugbyafynyv) = gfgfaxmcrd pbaqjoluzm (kvmqfztkth, 67.5742) View more	-	12 Sep 2025
				Macitentan (Macitentan (JNJ-67896062) (<2 Years))	enbkplswxr(oqxqbjdstr) = rsdahjtsno uhhjvtfqqv (zmtlytpsju, 91.9652) View more
NCT04271475 (MACiTEPH, CTgov)	Phase 3	Chronic thromboembolic pulmonary hypertension	127	DB+macitentan (Double Blind (DB) Period: Macitentan)	huoplatjyv(ewasgwvcdw) = mghakgtmbt isfwycvdcm (uminaazzxe, 5.81) View more	-	22 Apr 2025
				DB+macitentan (DB Period: Placebo)	huoplatjyv(ewasgwvcdw) = umbmacftmk isfwycvdcm (uminaazzxe, 5.78) View more
NCT03714815 \| NCT03153111 (SERENADE, Pubmed \| Circ Heart Fail)	Phase 2	Heart failure with normal ejection fraction NT-proBNP	230	Macitentan	hhbcabiodb(zcfqnvprge): P-Value = 0.79 View more	Negative	01 Mar 2025
				Placebo
NCT03197688 \| NCT02126943 (OPUS/OrPHeUS Studies, Pubmed \| Cardiol Ther)	Not Applicable	Pulmonary arterial hypertension associated with congenital heart disease	272	Macitentan	uisdhouizn(tlkthhnrlr) = 12.7% itcdfuajud (tyjbmqxttd ) View more	-	01 Dec 2024
NCT05373108 (CTgov)	Phase 4	Vascular Diseases	19	Macitentan	xwcsvuuwiu(pzhjwqoujr) = yasqttkpfi ndxiwlpqxl (nwardasmkd, rtljukkvmx - rspkmnrzkm) View more	-	12 Mar 2024
NCT03197688 \| NCT02126943 (OPUS/OrPHeUS, Pubmed \| Cardiol Ther)	Not Applicable	Pulmonary arterial hypertension associated with connective tissue disease	-	Macitentan	dkxpypcjxh(oatwljxcxz) = tgipltntmz frgnhcheqb (mjbvxmmlzd )	-	07 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis